Preclinical research showed antiproliferative activity against NRAS-mutant melanoma cell lines and antitumor activity against preclinical melanoma models.
Preclinical research showed antiproliferative activity against NRAS-mutant melanoma cell lines and antitumor activity against preclinical melanoma models.